Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia

The CD19 marker is expressed on the surface of normal and malignant immature or mature B-cells. On the other hand, immunotherapy involving T-cells is a promising modality of treatment for many neoplastic diseases including leukemias and lymphomas. The CD19/CD3-bispecific T-cell-engaging (BiTE(®)) mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribera, Josep-Maria, Ferrer, Albert, Ribera, Jordi, Genescà, Eulàlia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485855/
https://www.ncbi.nlm.nih.gov/pubmed/26170691
http://dx.doi.org/10.2147/OTT.S70524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485855/
https://www.ncbi.nlm.nih.gov/pubmed/26170691
http://dx.doi.org/10.2147/OTT.S70524

Ejemplares similares